Paula K. Cobb serves as Independent Director of the Company. Ms. Cobb is the chief operating officer of Decibel Therapeutics, Inc, a clinical-stage biotechnology company focused on drug discovery, development, and translational research for hearing and balance disorders. Until its acquisition by Biogen, Ms. Cobb served on the board of directors of Nightstar Therapeutics plc, a clinical-stage gene therapy company. Prior to joining Decibel in 2016, she worked in a variety of leadership and global roles at Biogen, including as senior vice president of the rare disease group, where she was responsible for the company's marketed hemophilia assets and Phase 3 programs in spinal muscular atrophy and neuropathic pain. Before Biogen, she worked for various consulting groups in the Boston area. Ms. Cobb graduated cum laude from Amherst College with a BA degree in political science and English. She also received an MBA from Harvard University's Graduate School of Business Administration.
As the Independent Director of Prothena plc, the total compensation of Paula Cobb at Prothena plc is $277,466. There are 12 executives at Prothena plc getting paid more, with Wagner Zago having the highest compensation of $3,341,640.
Paula's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Over the last 12 years, insiders at Prothena plc have traded over $79,429,035 worth of Prothena plc stock and bought 2,987,732 units worth $75,619,043 . The most active insiders traders include Capital, Llc Eco R1, Co Plc Elan Corp Plc Elan S... a Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of $946,769. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth $67,650.
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
Prothena plc executives and other stock owners filed with the SEC include: